Literature DB >> 8223770

Technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy in ulcerative colitis and Crohn's disease.

M Papós1, F Nagy, J Láng, L Csernay.   

Abstract

Technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy (LS) was performed on 45 occasions in 30 patients with ulcerative colitis and on 53 occasions in 34 patients with Crohn's disease. Serial images were taken following re-injection of the labelled leucocytes. The segmental extent of the inflammation and the grade of the leucocyte uptake were calculated, and compared with the laboratory results and colonoscopy findings. The sensitivity and specificity of LS proved higher in ulcerative colitis (87% and 93%) than in Crohn's disease (53% and 89% in cases with large intestine involvement, and 82% and 100% in cases with small intestine involvement). The activity of the process determined by LS correlates with the alpha 2-globulin level (r = 0.47), fibrinogen level (r = 0.50), fS iron level (r = -0.57), sedimentation (r = 0.44), leucocyte count (r = 0.38), platelet count (r = 0.34) and Best index (r = 0.31) in ulcerative colitis, but not in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223770     DOI: 10.1007/bf00180906

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  14 in total

1.  Technetium-99m hexamethyl propylene amine oxine leucocytes in the assessment of disease activity in inflammatory bowel disease.

Authors:  E Lantto; K Järvi; I Krekelä; T Lantto; M Taavitsainen; H Vedenkangas; M Vorne
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Inflammatory bowel disease (2)

Authors:  D K Podolsky
Journal:  N Engl J Med       Date:  1991-10-03       Impact factor: 91.245

3.  Radiochemical purity of [99mTc]HM-PAO.

Authors:  J R Ballinger; R H Reid; K Y Gulenchyn
Journal:  J Nucl Med       Date:  1988-04       Impact factor: 10.057

4.  Comparison of simultaneous 99mTc-HMPAO and 111In oxine labelled white cell scans in the assessment of inflammatory bowel disease.

Authors:  R A Allan; G E Sladen; S Bassingham; C Lazarus; S E Clarke; I Fogelman
Journal:  Eur J Nucl Med       Date:  1993-03

5.  Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents.

Authors:  J G McAfee; M L Thakur
Journal:  J Nucl Med       Date:  1976-06       Impact factor: 10.057

6.  Location and activity of ulcerative and Crohn's colitis by indium 111 leukocyte scan. A prospective comparison study.

Authors:  D T Stein; G M Gray; P B Gregory; M Anderson; D A Goodwin; I R McDougall
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

7.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

8.  Do technetium-99m hexamethylpropylene amine oxime-labeled leukocytes truly reflect the mucosal inflammation in patients with ulcerative colitis?

Authors:  S Almer; L Franzén; A M Peters; M Tjädermo; S Ekberg; G Granerus; M Ström
Journal:  Scand J Gastroenterol       Date:  1992-12       Impact factor: 2.423

9.  Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label.

Authors:  J Schölmerich; E Schmidt; C Schümichen; P Billmann; H Schmidt; W Gerok
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

10.  Value of positive technetium-99m leucocyte scans in predicting intestinal inflammation.

Authors:  P Gibson; M Lichtenstein; N Salehi; G Hebbard; J Andrews
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

View more
  5 in total

1.  Inflammatory bowel disease activity assessment using technetium-99m-HMPAO leukocytes.

Authors:  J W Arndt; M I Grootscholten; R A van Hogezand; G Griffioen; C B Lamers; E K Pauwels
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

2.  Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

Authors:  M H Giaffer
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

3.  Optimization of technetium-99m-HMPAO leukocyte scintigraphy in evaluation of active inflammatory bowel disease.

Authors:  M Sans; D Fuster; J Llach; F Lomeña; J M Bordas; R Herranz; J M Piqué; J Panés
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

4.  Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings.

Authors:  J J Kolkman; T H Falke; J C Roos; D H Van Dijk; I M Bannink; W Den Hollander; M A Cuesta; A S Peña; S G Meuwissen
Journal:  Dig Dis Sci       Date:  1996-04       Impact factor: 3.199

5.  Evaluation of Quantitative Imaging Biomarkers in the DSS Colitis Model.

Authors:  Anne Beltzer; Thomas Kaulisch; Teresa Bluhmki; Tanja Schoenberger; Birgit Stierstorfer; Detlef Stiller
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.